[{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"Allosteric tyrosine kinase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"TK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"NDI-034858","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"NDI-034858","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NDI-034858","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NDI-034858","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for NDI-034858

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TAK-279 is a highly selective, oral allosteric TYK2 inhibitor, which has potential to become an important treatment option in multiple immune-mediated inflammatory diseases.

                          Brand Name : TAK-279

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 11, 2023

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : TAK-279 (NDI-034858) is a late-stage, highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases.

                          Brand Name : NDI-034858

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 18, 2023

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Following the completion of this transaction, Takeda has now acquired TAK-279, formerly known at Nimbus as NDI-034858. This acquisition strengthens Takeda’s growing late-stage pipeline and potentially expands its portfolio and patient impact across mul...

                          Brand Name : TAK-279

                          Molecule Type : Small molecule

                          Upfront Cash : $4,000.0 million

                          February 08, 2023

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : $6,000.0 million

                          Deal Type : Agreement

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The acquisition strengthens Takeda's autoimmune portfolio, preferably NDI-034858 candidate, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases, especilally moderate to severe plaque psoriasis.

                          Brand Name : NDI-034858

                          Molecule Type : Small molecule

                          Upfront Cash : $4,000.0 million

                          December 13, 2022

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : $6,000.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NDI-034858 is an allosteric TYK2 inhibitor developed by Nimbus Therapeutics that is being evaluated for the treatment of multiple autoimmune diseases. In preclinical studies, NDI-034858 has demonstrated exceptional functional selectivity and wide therape...

                          Brand Name : NDI-034858

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 30, 2022

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : In a Phase 1 clinical study, NDI-034858 demonstrated a good tolerability profile and evidence of clinical and pharmacodynamic activity across multiple measures of disease pathology in psoriasis.

                          Brand Name : NDI-034858

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 24, 2022

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The pharmacokinetic profile of NDI-034858 observed in healthy volunteers supports the potential for once-daily dosing, with 50 mg expected to cover IC90 for 24 hours.

                          Brand Name : NDI-034858

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 19, 2022

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Nimbus’ data indicate that treatment with NDI-034858 resulted in improvement across multiple measures of disease pathology and normalization of molecular and inflammatory pathways dysregulated in psoriasis.

                          Brand Name : NDI-034858

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 25, 2022

                          Lead Product(s) : NDI-034858

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank